» Articles » PMID: 31018748

Anti-tumor Activity and Mechanism of Oligoclonal Hepatocellular Carcinoma Tumor-infiltrating Lymphocytes and

Overview
Specialties Oncology
Pharmacology
Date 2019 Apr 26
PMID 31018748
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

: To explore a method for culturing hepatocellular carcinoma and tumor-infiltrating lymphocytes (HCC-TIL) and investigate the mechanism of TIL in killing tumors. : The distribution of regulatory T cells (Treg) in HCC was detected by immunohistochemistry. Conventional TIL and oligoclonal TIL were isolated by the traditional method of enzyme digestion combined with mechanical treatment for whole HCC and micro HCC tissue block culturing method. MTT was used to compare the killing activity of TIL. Flow cytometry was used to analyze the proportion of CD8 T cells and Treg cells in TIL. Tumor-bearing mice were established, and TIL adoptive immunotherapy was performed. : Treg cells were mainly distributed in the stroma of HCC. experiments showed oligoclonal TIL had higher cytotoxicity to tumor cells which negatively correlated with the proportion of Treg cells. experiments showed oligoclonal TIL had a higher anti-tumor effect. IFN-γ in peripheral blood and the positive rate of intratumoral lymphocytic infiltration in oligoclonal TIL group were both higher. TGF-β and IL-10 in peripheral blood and the positive rate of intratumoral FoxP3 and IL-17 were both lower than those in conventional TIL group. : The oligoclonal TIL culture method could obtain TIL with higher purity, and cytotoxicity to tumor cells was associated with Treg cells. The oligoclonal TIL had cytotoxicity to autologous HCC cells and significant inhibitory effect on the growth of transplanted tumors. The mechanism might be associated with the inhibition of Treg cells proliferation, increase of IFN-γ secretion, and decrease of TGF-β, IL-10, and IL-17 secretion.

Citing Articles

Revolutionizing Pathology with Artificial Intelligence: Innovations in Immunohistochemistry.

Poalelungi D, Neagu A, Fulga A, Neagu M, Tutunaru D, Nechita A J Pers Med. 2024; 14(7).

PMID: 39063947 PMC: 11278211. DOI: 10.3390/jpm14070693.


Developing innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment.

Yu Z, Shi J, Fang Y, Zhao Y, Xu A, Li N Oncol Rep. 2024; 51(6).

PMID: 38666543 PMC: 11082634. DOI: 10.3892/or.2024.8744.


The molecular mechanism of actions and clinical utilities of tumor infiltrating lymphocytes in gastrointestinal cancers: a comprehensive review and future prospects toward personalized medicine.

Piroozkhah M, Gholinezhad Y, Piroozkhah M, Shams E, Nazemalhosseini-Mojarad E Front Immunol. 2023; 14:1298891.

PMID: 38077386 PMC: 10704251. DOI: 10.3389/fimmu.2023.1298891.


Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma.

Li Z, Zhang Z, Fang L, Zhao J, Niu Z, Chen H J Hepatocell Carcinoma. 2023; 10:2083-2099.

PMID: 38022729 PMC: 10676104. DOI: 10.2147/JHC.S436962.


Changes in Inflammatory Markers Predict the Prognosis of Resected Hepatocellular Carcinoma with Child-Pugh A.

Zhou J, Yang D Curr Oncol. 2022; 29(8):5800-5809.

PMID: 36005195 PMC: 9406633. DOI: 10.3390/curroncol29080457.


References
1.
Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163(10):5211-8. View

2.
Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

3.
Unitt E, Rushbrook S, Marshall A, Davies S, Gibbs P, Morris L . Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005; 41(4):722-30. DOI: 10.1002/hep.20644. View

4.
Thomas D, Massague J . TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005; 8(5):369-80. DOI: 10.1016/j.ccr.2005.10.012. View

5.
Zou W . Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006; 6(4):295-307. DOI: 10.1038/nri1806. View